PE20030329A1 - Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo - Google Patents
Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismoInfo
- Publication number
- PE20030329A1 PE20030329A1 PE2002000719A PE2002000719A PE20030329A1 PE 20030329 A1 PE20030329 A1 PE 20030329A1 PE 2002000719 A PE2002000719 A PE 2002000719A PE 2002000719 A PE2002000719 A PE 2002000719A PE 20030329 A1 PE20030329 A1 PE 20030329A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- amino
- methyl
- ring
- link
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 title abstract 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- -1 AMINO Chemical group 0.000 abstract 4
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 230000001413 cellular effect Effects 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 abstract 1
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 abstract 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 229960001830 amprenavir Drugs 0.000 abstract 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 230000001351 cycling effect Effects 0.000 abstract 1
- 229960002656 didanosine Drugs 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 150000002430 hydrocarbons Chemical class 0.000 abstract 1
- 229960001936 indinavir Drugs 0.000 abstract 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 229960000884 nelfinavir Drugs 0.000 abstract 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 abstract 1
- 229960001852 saquinavir Drugs 0.000 abstract 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical compound S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960002555 zidovudine Drugs 0.000 abstract 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/16—Eight-membered rings
- C07D313/20—Eight-membered rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001240750 | 2001-08-08 | ||
| JP2002066809 | 2002-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030329A1 true PE20030329A1 (es) | 2003-05-12 |
Family
ID=26620186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000719A PE20030329A1 (es) | 2001-08-08 | 2002-08-07 | Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo |
Country Status (13)
| Country | Link |
|---|---|
| US (7) | US7371772B2 (enExample) |
| EP (3) | EP2206702B1 (enExample) |
| JP (4) | JP4316203B2 (enExample) |
| AR (1) | AR034985A1 (enExample) |
| AT (2) | ATE460406T1 (enExample) |
| AU (1) | AU2002328092A1 (enExample) |
| CA (2) | CA2607992A1 (enExample) |
| DE (1) | DE60235632D1 (enExample) |
| DK (2) | DK2206702T3 (enExample) |
| ES (2) | ES2339340T3 (enExample) |
| PE (1) | PE20030329A1 (enExample) |
| PT (2) | PT1423376E (enExample) |
| WO (1) | WO2003014105A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60235632D1 (de) | 2001-08-08 | 2010-04-22 | Tobira Therapeutics Inc | Bicyclische verbindung, deren herstellung und verwendung |
| EP1484322A4 (en) * | 2002-03-12 | 2008-01-23 | Takeda Pharmaceutical | PROCESS FOR PRODUCING AN OPTICALLY ACTIVE SULFOXIDE DERIVATIVE |
| WO2004069834A1 (ja) * | 2003-02-07 | 2004-08-19 | Takeda Pharmaceutical Company Limited | 三環性化合物、その製造方法および用途 |
| US7288654B2 (en) | 2003-02-07 | 2007-10-30 | Takeda Pharmaceutical Company Ltd | Fused-ring pyridine derivative, process for producing the same, and use |
| US20060160864A1 (en) * | 2003-02-07 | 2006-07-20 | Mitsuru Shiraishi | Acrylamide derivative, process for producing the same, and use |
| US20080249147A1 (en) * | 2004-03-24 | 2008-10-09 | Takeda Pharmaceutical Company Limited | Emulsion-Stabilized Preparation |
| EP1728505B1 (en) * | 2004-03-24 | 2014-06-04 | Takeda Pharmaceutical Company Limited | Preparation with elevated content |
| US20050260139A1 (en) * | 2004-03-30 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on anticholinergics and CCR2 receptor antagonists |
| JP2007269628A (ja) * | 2004-05-28 | 2007-10-18 | Takeda Chem Ind Ltd | 医薬化合物の結晶 |
| JPWO2006059716A1 (ja) * | 2004-12-03 | 2008-06-05 | 武田薬品工業株式会社 | 固形製剤 |
| US8426387B2 (en) * | 2006-03-31 | 2013-04-23 | Stephen Carper | Treatments for cancer |
| WO2008030853A2 (en) * | 2006-09-06 | 2008-03-13 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| TWI499414B (zh) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| US7846945B2 (en) * | 2007-03-08 | 2010-12-07 | Lexicon Pharmaceuticals, Inc. | Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use |
| CN102256970A (zh) * | 2008-10-17 | 2011-11-23 | 因瓦斯科医疗有限公司 | 用于治疗肾活素-血管紧张素醛固酮系统(raas)相关性障碍的组合物以及方法 |
| NZ625712A (en) | 2009-11-27 | 2016-02-26 | Genzyme Corp | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| PE20130529A1 (es) | 2010-04-02 | 2013-05-14 | Phivco 1 Llc | Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico |
| WO2012047630A2 (en) * | 2010-09-27 | 2012-04-12 | Martin Teintze | N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use |
| EP2741777B1 (en) | 2011-08-12 | 2017-01-18 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| RU2020119611A (ru) | 2014-03-21 | 2020-06-29 | Тобира Терапьютикс, Инк. | Сенекривирок для лечения фиброза |
| US20170105969A1 (en) * | 2014-06-02 | 2017-04-20 | Tobira Therapeutics, Inc. | Cenicriviroc for the treatment of hiv-2 infection |
| CN106999593A (zh) | 2014-09-12 | 2017-08-01 | 妥必徕疗治公司 | 用于纤维化治疗的赛尼克韦罗组合疗法 |
| CN112266392A (zh) | 2014-12-23 | 2021-01-26 | 妥必徕疗治公司 | 制备cenicriviroc及相关类似物的方法 |
| EP3256124B1 (en) | 2015-02-10 | 2020-12-23 | Tobira Therapeutics, Inc. | Composition comprising cenicriviroc and fumaric acid for use in the treatment of acute liver injury or peritonitis |
| KR101938036B1 (ko) * | 2015-04-16 | 2019-01-14 | 서울대학교산학협력단 | 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법 |
| WO2017223155A1 (en) * | 2016-06-21 | 2017-12-28 | Tobira Therapeutics, Inc. | Purified cenicriviroc and purified intermediates for making cenicriviroc |
| RU2019109019A (ru) * | 2016-08-31 | 2020-10-01 | Тобира Терапьютикс, Инк. | Твердые формы ценикривирок мезилата и способы изготовления твердых форм ценикривирок мезилата |
| WO2018103757A1 (zh) * | 2016-12-09 | 2018-06-14 | 广东众生药业股份有限公司 | 作为ccr2/ccr5受体拮抗剂的联苯化合物 |
| EA201991990A1 (ru) | 2017-02-24 | 2020-04-07 | Женфит | Фармацевтические композиции для комбинированной терапии |
| KR20200116912A (ko) | 2018-02-02 | 2020-10-13 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 카르복실산기를 포함하는 질소-함유 벤조헤테로시클 화합물, 이의 제조 방법 및 이의 용도 |
| EP3749697A4 (en) | 2018-02-05 | 2021-11-03 | Bio-Rad Laboratories, Inc. | CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE |
| WO2019238041A1 (zh) * | 2018-06-12 | 2019-12-19 | 南京明德新药研发有限公司 | 一种丙烯酰胺类化合物的晶型及其制备方法 |
| CN113412261A (zh) * | 2019-04-08 | 2021-09-17 | 四川科伦博泰生物医药股份有限公司 | 苯并咪唑化合物、其制备方法及其用途 |
| US20230002360A1 (en) * | 2019-06-24 | 2023-01-05 | Shenzhen Lingfang Biotech Co.,Ltd | Heterocycloalkyl compounds as CCR2 / CCR5 antagonists |
| WO2021133811A1 (en) | 2019-12-26 | 2021-07-01 | Teva Pharmaceuticals International Gmbh | Solid state forms of cenicriviroc and process for preparation thereof |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
| WO2021233349A1 (zh) | 2020-05-22 | 2021-11-25 | 南京明德新药研发有限公司 | 吡啶类衍生物及其应用 |
| CN112472678A (zh) * | 2020-11-12 | 2021-03-12 | 澳美制药厂有限公司 | 肾素那敏制剂及其制备方法 |
| WO2023143112A1 (zh) * | 2022-01-26 | 2023-08-03 | 无锡瓴方生物医药科技有限公司 | 氮杂苯并八元环化合物的盐型、晶型及其应用 |
| WO2024240025A1 (zh) * | 2023-05-22 | 2024-11-28 | 无锡瓴方生物医药科技有限公司 | 一种联合用药物组合物及其应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62265270A (ja) | 1986-05-13 | 1987-11-18 | Zeria Shinyaku Kogyo Kk | 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤 |
| DE69520360T2 (de) | 1994-07-04 | 2001-08-09 | Takeda Chemical Industries, Ltd. | Phosphonsäure verbindungen imre herstellung und verwendung |
| RU2167649C2 (ru) | 1995-08-11 | 2001-05-27 | Ниссан Кемикал Индастриз, Лтд. | Способ получения твердой дисперсии умеренно водорастворимого лекарственного вещества (варианты) и фармацевтическая композиция |
| WO1999020276A1 (fr) | 1997-10-20 | 1999-04-29 | Dainippon Pharmaceutical Co., Ltd. | Composition medicamenteuse stable |
| CN1282243A (zh) * | 1997-12-19 | 2001-01-31 | 武田药品工业株式会社 | 用于拮抗ccr5的含n－酰苯胺衍生物的药物组合物 |
| AU5301599A (en) | 1998-08-20 | 2000-03-14 | Takeda Chemical Industries Ltd. | Quaternary ammonium salts and their use |
| CA2244097A1 (en) | 1998-08-21 | 2000-02-21 | Bernard Charles Sherman | Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid |
| WO2000037455A1 (en) | 1998-12-21 | 2000-06-29 | Takeda Chemical Industries, Ltd. | Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5 |
| WO2000061109A1 (fr) | 1999-04-12 | 2000-10-19 | Shionogi & Co., Ltd. | Procede de production de composition medicamenteuse renfermant un compose medicamenteux hydrophobe basique |
| JP2001026586A (ja) | 1999-05-07 | 2001-01-30 | Takeda Chem Ind Ltd | 環状化合物およびその用途 |
| WO2001017947A1 (en) | 1999-09-06 | 2001-03-15 | Takeda Chemical Industries, Ltd. | Process for the preparation of 2,3-dihydroazepine compounds |
| DE60235632D1 (de) * | 2001-08-08 | 2010-04-22 | Tobira Therapeutics Inc | Bicyclische verbindung, deren herstellung und verwendung |
| EP1484322A4 (en) | 2002-03-12 | 2008-01-23 | Takeda Pharmaceutical | PROCESS FOR PRODUCING AN OPTICALLY ACTIVE SULFOXIDE DERIVATIVE |
| EP1728505B1 (en) * | 2004-03-24 | 2014-06-04 | Takeda Pharmaceutical Company Limited | Preparation with elevated content |
| US20080249147A1 (en) * | 2004-03-24 | 2008-10-09 | Takeda Pharmaceutical Company Limited | Emulsion-Stabilized Preparation |
| JPWO2006059716A1 (ja) | 2004-12-03 | 2008-06-05 | 武田薬品工業株式会社 | 固形製剤 |
| WO2008030853A2 (en) | 2006-09-06 | 2008-03-13 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| PE20130529A1 (es) | 2010-04-02 | 2013-05-14 | Phivco 1 Llc | Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico |
| PE20140406A1 (es) | 2010-11-18 | 2014-04-16 | Univ Yale | Moleculas bifuncionales con actividad de reclutamiento de anticuerpos y actividad inhibitoria inicial contra el virus de la inmunodeficiencia humana |
| ES2636679T3 (es) | 2011-06-27 | 2017-10-06 | Université Pierre Et Marie Curie (Paris 6) | Péptidos antagonistas de CCR2 |
| UA115807C2 (uk) | 2013-05-15 | 2017-12-26 | Тобіра Терап'Ютикс, Інк. | Композиція (варіанти) ценікривіроку і спосіб її одержання та застосування (варіанти) |
| RU2020119611A (ru) | 2014-03-21 | 2020-06-29 | Тобира Терапьютикс, Инк. | Сенекривирок для лечения фиброза |
| CN112266392A (zh) | 2014-12-23 | 2021-01-26 | 妥必徕疗治公司 | 制备cenicriviroc及相关类似物的方法 |
| EP3256124B1 (en) | 2015-02-10 | 2020-12-23 | Tobira Therapeutics, Inc. | Composition comprising cenicriviroc and fumaric acid for use in the treatment of acute liver injury or peritonitis |
-
2002
- 2002-08-07 DE DE60235632T patent/DE60235632D1/de not_active Expired - Lifetime
- 2002-08-07 ES ES02762751T patent/ES2339340T3/es not_active Expired - Lifetime
- 2002-08-07 CA CA002607992A patent/CA2607992A1/en not_active Abandoned
- 2002-08-07 ES ES10150963T patent/ES2376855T3/es not_active Expired - Lifetime
- 2002-08-07 AU AU2002328092A patent/AU2002328092A1/en not_active Abandoned
- 2002-08-07 AR ARP020102986A patent/AR034985A1/es not_active Application Discontinuation
- 2002-08-07 CA CA2459172A patent/CA2459172C/en not_active Expired - Lifetime
- 2002-08-07 PE PE2002000719A patent/PE20030329A1/es not_active Application Discontinuation
- 2002-08-07 EP EP10150963A patent/EP2206702B1/en not_active Expired - Lifetime
- 2002-08-07 PT PT02762751T patent/PT1423376E/pt unknown
- 2002-08-07 PT PT10150963T patent/PT2206702E/pt unknown
- 2002-08-07 EP EP07021230.3A patent/EP1889839B1/en not_active Expired - Lifetime
- 2002-08-07 AT AT02762751T patent/ATE460406T1/de active
- 2002-08-07 AT AT10150963T patent/ATE539062T1/de active
- 2002-08-07 DK DK10150963.6T patent/DK2206702T3/da active
- 2002-08-07 DK DK02762751.2T patent/DK1423376T3/da active
- 2002-08-07 JP JP2002229532A patent/JP4316203B2/ja not_active Expired - Lifetime
- 2002-08-07 US US10/484,762 patent/US7371772B2/en not_active Expired - Lifetime
- 2002-08-07 EP EP02762751A patent/EP1423376B1/en not_active Expired - Lifetime
- 2002-08-07 WO PCT/JP2002/008043 patent/WO2003014105A1/en not_active Ceased
-
2006
- 2006-12-28 JP JP2006355701A patent/JP4358851B2/ja not_active Expired - Lifetime
-
2007
- 2007-10-25 US US11/978,198 patent/US8183273B2/en active Active
-
2008
- 2008-05-12 US US12/119,355 patent/US8362058B2/en not_active Expired - Fee Related
-
2009
- 2009-06-22 JP JP2009147839A patent/JP5275148B2/ja not_active Expired - Lifetime
-
2012
- 2012-05-21 US US13/476,454 patent/US8741943B2/en not_active Expired - Lifetime
-
2013
- 2013-03-13 JP JP2013050937A patent/JP2013136629A/ja active Pending
-
2014
- 2014-04-25 US US14/261,683 patent/US10045968B2/en not_active Expired - Lifetime
-
2018
- 2018-08-08 US US16/058,303 patent/US20190038604A1/en not_active Abandoned
-
2020
- 2020-01-23 US US16/750,977 patent/US20200297700A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030329A1 (es) | Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo | |
| CL2023003583A1 (es) | Inhibidores de pi3k y métodos de uso de los mismos div 2985-22 | |
| CO2023014807A2 (es) | Compuesto cíclico que contiene acción inhibidora selectiva en kras por sobre hras y nras | |
| BR112021023814A2 (pt) | Inibidores de proteases de cisteína e métodos de uso das mesmas | |
| CL2023002276A1 (es) | Inhibidores de cdk y métodos de uso de estos | |
| BR112021022796A2 (pt) | Inibidores de inflamassoma de nlrp3 | |
| EA200401437A1 (ru) | Ненуклеозидные ингибиторы обратной транскриптазы для лечения вич инфекции, способ их получения (варианты), способ увеличения периода полупревращения ненуклеозидного соединения, обладающего активностью против ретровирусов, и способ получения фармацевтической композиции, обладающей специфичностью к лейкоцитам | |
| BRPI0411155A (pt) | composto que se liga a e ativa o receptor de eritropoietina, composição farmacêutica e seu uso | |
| NI200900053A (es) | Composiciones de fenilalquilamino carbamato | |
| BR0014602A (pt) | Hexaidrofluoro'2,3-bifuran-3-il-n-{3'(1,3-benzodioxol- 5ilsulfonil)(isobutil)amino-1 -benzil-2-hidroxipropil}carbamato como inibidor da protease retroviral | |
| BRPI0412893A (pt) | composto, composição farmacêutica, uso de um composto, e, métodos de prevenção, tratamento ou melhora de doenças ou condições inflamatórias, ou doenças ou condições oftálmicas, de tratamento ou melhora de cáncer e para a produção de um composto | |
| AR039352A1 (es) | Uso de un compuesto que tiene actividad inhibitoria combinada y concurrente con endopeptidasa neutra y metaloproteasa igs5. | |
| BRPI0409928B8 (pt) | composto, composição farmacêutica, uso do composto e processo para a fabricação do mesmo | |
| AR129281A1 (es) | INHIBIDORES DE PI3Ka Y MÉTODOS DE USO DE LOS MISMOS | |
| PE20212111A1 (es) | Moduladores calpaina y usos terapeuticos de los mismos | |
| MX2022015524A (es) | Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas. | |
| BRPI0513858B8 (pt) | compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende | |
| MX2022001743A (es) | Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahi dronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma. | |
| MX2024010334A (es) | Composicion farmaceutica que comprende anticuerpo biespecifico anti-ctla4-anti-pd-1 y chiauranib. | |
| BR112022008183A2 (pt) | Formas de sal de um receptor de c5a de componente do complemento | |
| CO2024012622A2 (es) | Anticuerpos capaces de unirse a la proteína de la espícula de coronavirus sars-cov-2 | |
| BR0306927A (pt) | Compostos tricìclicos de 2-pirimidona úteis como inibidores de transcriptase reversa de hiv | |
| DK1735296T3 (da) | Materialer og fremgangsmåder til behandling af koagulationslidelser | |
| CL2023001268A1 (es) | Composiciones farmacéuticas de un inhibidor de cinasa | |
| EA202191150A1 (ru) | Ингибиторы аминопептидазы а и содержащие их фармацевтические композиции |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |